News & Publications

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

December 7, 2017

Category

PARI News

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

Published

November 10, 2017

Category

Publications

In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution.

Published

November 18, 2015

Category

Publications

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

Published

June 3, 2015

Category

PARI Publications

In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent®).

Published

August 1, 2014

Category

Publications

Drug delivery to paranasal sinuses using pulsating aerosols.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

News, Publications & Insights

In the Spotlight

Partner Project News

PARI Publication

MagnairTM an eFlow® Closed System Nebulizer together with Sunovion’s LonhalaTM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution.

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent®).

Drug delivery to paranasal sinuses using pulsating aerosols.

Contact us

PARI Business Development Team